zs pharma acquisition

ZS Pharma, based in San Mateo, Calif., employs about 200 people in three states. accepted for payment in the tender offer (excluding shares held as treasury Thomas Kudsk Larsen Oncology +44 7818 524185 The deal, approved by the Board of Directors of ZS Pharma, will give AstraZeneca access to its potassium-binding compound ZS-9, a potential treatment for hyperkalaemia, which is under review by the US Food and Drug Administration (FDA). AstraZeneca is a global, innovation-driven biopharmaceutical business that The ZS-9 insoluble, non-absorbed zirconium silicate traps potassium ions with its three-dimensional crystalline lattice structure. owned subsidiary of AstraZeneca. Business, News & Multimedia, Photos, Reports, Investment news, Personal finance As with any acquisition, it is also currently going through the growing pains of integrating some areas with the parent organization, and keeping other parts intact. The company has been focused on using its proprietary AstraZeneca strengthens cardiovascular and metabolic disease portfolio with acquisition of ZS Pharma Details AstraZeneca 06 November 2015 AstraZeneca announced today that it has entered into a definitive agreement to acquire ZS Pharma (NASDAQ: ZSPH), a biopharmaceutical company based in San Mateo, California. After the acceptance of shares that were validly tendered and not withdrawn with a Prescription Drug User Fee Act goal date of 26 May 2016. acquisition of ZS Pharma as previously announced in AstraZeneca announced that the company successfully completed the tender offer for all of the outstanding shares of ZS Pharma and the subsequent acquisition of ZS Pharma as previously announced in November. Sorry, your blog cannot share posts by email. ZS-9 complements AstraZeneca’s increasing focus on CKD and CHF, including the investigational medicine roxadustat, which is currently in Phase III development for patients with anaemia associated with CKD, as well as its leading diabetes portfolio. AstraZeneca has completed its previously announced tender offer for all of the outstanding shares of ZS Pharma, a biopharmaceutical company based in San Mateo, California, for $2.7 billion, and the subsequent acquisition of the company. If approved by the FDA, ZS-9 is expected to generate sales of more than $1bn a year. AstraZeneca chief executive officer Pascal Soriot said: "Hyperkalaemia can be a life-threatening condition for patients with chronic kidney disease and chronic heart failure, however the risk is under-appreciated and prevalence is increasing. Following completion of the merger, associated with chronic kidney disease, in patients on dialysis and those who The purpose of the Merger is to acquire all capital stock of ZS Pharma not purchased pursuant to the Offer or otherwise and to cause ZS Pharma to become a wholly owned subsidiary of Parent. ", 8 November 2015 (Last Updated November 8th, 2015 18:30). ion-trap technology to develop new treatments of kidney and liver diseases that The global development programme is being conducted by Source: 4-traders ZS Pharma: ZS Pharma : AstraZeneca completes acquisition of ZS Pharma (4-traders.com) AstraZeneca announced today the successful completion of the tender offer for all of the outstanding shares of ZS Pharma (NASDAQ: ZSPH) and the subsequent acquisition of ZS Pharma as previously announced in November. FibroGen in collaboration with AstraZeneca and Astellas. AstraZeneca announced today the successful completion of the tender offer for The transaction strengthens AstraZeneca’s cardiovascular and … 17 December 2015. -9 complements the Company’s increasing focus on CKD and CHF, including the In a long-term safety and efficacy study, ZS-9 lowered serum potassium, maintained normokalemia, and was well tolerated for about 52 weeks. chronic kidney disease (CKD), diabetes mellitus (DM), and chronic heart failure Cardiovascular, metabolic disease and chronic kidney disease are key areas of ZS-9 is under regulatory review by the US Food and Drug Administration This new group is AZ's play in the bay area to compete with the other big pharma innovative players in California. We look forward to welcoming the ZS Pharma team to AstraZeneca.". “WILL,” “MAY,” “SHOULD,” “ESTIMATE,” “PREDICT,” “POTENTIAL,” “CONTINUE” OR THE DISCUSSED IN THE FORWARD-LOOKING STATEMENTS, AND YOU SHOULD NOT PLACE UNDUE connection with the merger, each outstanding share of ZS Pharma that was not The US firm uses its ion­-trap technology to develop new treatments for hyperkalaemia, a serious condition of high potassium levels in the bloodstream, typically associated with chronic kidney disease (CKD) and chronic heart failure (CHF). Vanessa Rhodes UK/Global +44 20 7604 8037 Lindsey Trickett Oncology, ING +1 240 543 7970 American Rescue Plan is a watershed moment for US recovery – leading macroeconomic influencers, Incyte’s Covid-19 associated ARDS study fails to meet primary endpoint, Medolife Rx reports positive data from Covid-19 drug candidate study, Exscientia raises $100m Series C funding to develop fully autonomous drug design, Takeda exercises option to acquire Maverick Therapeutics for $525m, Amgen signs agreement to acquire Five Prime Therapeutics for $1.9bn, EMA review concludes AstraZeneca Covid-19 vaccine is “safe and effective”, Pfizer/BioNTech’s Comirnaty forecast to reach record-breaking peak sales within two years of launch, Moving towards COVID-safe workspaces with the Nymi Band™️, Federal Trade Commission forms multilateral working group on pharma mergers, Philippines approves Sputnik V Covid-19 vaccine for emergency use. focus for AstraZeneca as part of the company’s strategy for achieving scientific We connect the dots across organizations leveraging analytics, technology and strategy to deliver solutions to the most difficult business challenges. THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION (SEC), INCLUDING THE “RISK respiratory, inflammation, autoimmune, oncology, infection and neuroscience AstraZeneca announced today the successful completion of the tender offer for all of the outstanding shares of ZS Pharma (NASDAQ: ZSPH) and the subsequent acquisition of ZS Pharma as previously announced in November.. for patients with anaemia associated with CKD, as well as its leading diabetes AstraZeneca COMPLETES ACQUISITION OF ZS PHARMA AstraZeneca announced today the successful completion of the tender offer for all of the outstanding shares of ZS Pharma … The Offer, as the first step in the acquisition of ZS Pharma, is intended to facilitate the acquisition of all of the Shares. INVOLVE KNOWN AND UNKNOWN RISKS, UNCERTAINTIES AND OTHER FACTORS THAT MAY CAUSE UK You may ask if in view of this acquisition, I might step up on Relypsa which has a competitive product to ZS Pharma’s ZS-9 called patiromer. Post was not sent - check your email addresses! The acquisition is structured as an all-cash tender offer for all outstanding shares of ZS common stock, followed by a merger in which each remaining untendered share of ZS Pharma common stock would be converted into the same $90 cash per share consideration as in the tender offer. The board of ZS Pharma has unanimously approved the terms of the agreement. investigational medicine roxadustat, which is currently in Phase III development AND THE TIMING OF EVENTS MAY DIFFER MATERIALLY FROM THE RESULTS AND/OR TIMING One of the innovative medicines currently in November (https://www.astrazeneca.com/our-company/media-centre/press Announces Completion of Private Placement with Birchtree Investments Ltd. shares of ZS Pharma common stock were validly tendered and not withdrawn RESULTS, LEVELS OF ACTIVITY, PERFORMANCE OR ACHIEVEMENTS TO BE MATERIALLY Canada's Leading Online Business Magazine. Astrazeneca, UK's second-largest drugmaker, agreed to buy ZS Pharma for $2.7 billion in cash, sweeping it from Swiss rival Actelion. Eugenia Litz RIA +44 7884 735627 addressing the multiple risk factors facing CVMD and CKD patients at different RELIANCE ON THESE STATEMENTS. Jacob Lund Sweden +46 8 553 260 20 ZS Pharma’s shares ceased to be listed on NASDAQ, and ZS Pharma became a wholly With AstraZeneca’s $2.7bn purchase of ZS Pharma and its hyperkalaemia project ZS-9 turning increasingly sour, its rival Relypsa became a prominent acquisition target. OCCURRING AFTER THE DATE HEREOF OR OTHERWISE. Mitch Chan Oncology +1 240 477 3771 AstraZeneca operates in over 100 countries and its innovative The tender offer expired at 00:00 EST on 16 December 2015 and was not extended. ZS Pharma uses its proprietary ion­-trap technology to develop novel treatments for hyperkalaemia (high … The acquisition is structured as an all-cash tender offer for all outstanding shares of ZS Pharma common stock at a price of $90 per share, followed by … TENDER OFFER DOCUMENTS FILED BY SUBSIDIARIES OF ASTRAZENECA AND THE ZS Pharma develops and commercialises highly selective, non-absorbed drugs to treat renal, cardiovascular, liver and metabolic disorders. diseases. THESE STATEMENTS ARE GENERALLY IDENTIFIED The transaction strengthens AstraZeneca’s cardiovascular and metabolic disease ZS Pharma, founded in 2008, is a publicly traded biopharmaceutical company SOME OF THE STATEMENTS CONTAINED IN THIS ANNOUNCEMENT ARE FORWARD LOOKING Boston Pharma signs out-licensing agreement with GSK, Anima and Takeda to develop mRNA modulators for neurological diseases, Gilead and Novo Nordisk expand collaboration for NASH clinical study, Logging in: how the pharma industry is getting to grips with social media. pursuant to the tender offer, AstraZeneca completed its acquisition of ZS Pharma The acquisition represents a gamble by AstraZeneca on ZS-9 winning a green light from regulators; it said potential peak global sales for the drug were estimated to exceed $1bn. (CVMD) portfolio with the addition of the potassium-binding compound ZS-9 So the real surprise is not that Relypsa was sold, which happened this morning, but that its buyer should be the low-profile Swiss company Galenica. AstraZeneca COMPLETES ACQUISITION OF ZS PHARMA. "This acquisition complements our strategic focus on Cardiovascular and Metabolic Disease by adding a potential best-in-class treatment to our portfolio of innovative medicines. focuses on the discovery, development and commercialisation of prescription The transaction strengthens AstraZeneca’s cardiovascular and metabolic disease (CVMD) portfolio with the addition of the potassium-binding compound ZS-9 (sodium … STATEMENTS, INCLUDING THE POSSIBILITY THAT THE TRANSACTION WILL NOT BE COMPLETED Craig Marks Finance +44 7881 615764 ZS Pharma represents a strong fit with AstraZeneca’s pipeline and portfolio in Cardiovascular & Metabolic Disease, one of the company’s three main therapy areas. George Media Inc. All rights reserved. (CHF). © Copyright 2021 The Canadian Business Journal. Photo: courtesy of AstraZeneca. ZS Pharma develops and commercialises highly selective, non-absorbed drugs to treat renal, cardiovascular, liver and metabolic disorders. If you continue to use this site we will assume that you are happy with it. Clearly, there was a bidding war for ZS Pharma. DIFFERENT FROM ANY FUTURE STATEMENTS. taxes, the same as the tender offer price. Michele Meixell US +1 302 885 2677 AstraZeneca has agreed to buy ZS Pharma, the US biotech company, for $2.7bn (£1.8bn) in cash, thwarting the ambitions of a Swiss rival in the deal-hungry pharmaceutical sector. hyperkalaemia, a condition associated with increased mortality in patients with "We look forward to joining AstraZeneca and to working together to bring this important treatment for hyperkalaemia to the global market, helping to meet an important unmet medical need for patients.". A submission for all of the outstanding shares of ZS Pharma (NASDAQ: ZSPH) and the subsequent ZS Pharma acquisition complements AstraZeneca’s pipeline and portfolio. All shares that were validly tendered and not AstraZeneca COMPLETES ACQUISITION OF ZS PHARMA . -portfolio-with-acquisition-of-ZS-Pharma-06112015.html). The acquisition is structured as an all-cash tender offer for all outstanding shares of ZS Pharma common stock at a price of $90 per share, followed by a merger in which each remaining untendered share of ZS Pharma common stock would be converted into the same $90 … DECEMBER 31, 2014 AND SUBSEQUENT QUARTERLY REPORTS ON FORM 10-Q, AS WELL AS THE options have been limited. ZS-9 is being reviewed by the Food and Drug Administration, with a decision expected in May. As of the expiration of the tender offer, a total of approximately 21,948,939 PROVE INACCURATE OR UNKNOWN RISKS OR UNCERTAINTIES MATERIALIZE, ACTUAL RESULTS ZS $90.00 per share in cash, without interest and less any required withholding are not on dialysis. We use cookies to ensure that we give you the best experience on our website. The transaction strengthens AstraZeneca’s cardiovascular and metabolic disease (CVMD) portfolio with the addition of the potassium-binding compound ZS … ASTRAZENECA COMPLETES ACQUISITION OF ZS PHARMA Thu, Dec 17, 2015 15:16 CET. Under the deal, AstraZeneca will pay $90 a share for ZS Pharma, which employs about 200 people across three sites in California, Texas and Colorado. ZS Pharma uses its proprietary ion­-trap technology to develop novel treatments for hyperkalaemia (high potassium levels), a serious condition of elevated potassium in the bloodstream, typically associated with chronic kidney disease (CKD) and … stages of their disease, with the goal of reducing morbidity and mortality medicines are used by millions of patients worldwide. are focused on addressing unmet needs in the medical community. AstraZeneca’s strategy focuses on reducing morbidity, mortality and organ damage by addressing multiple risk factors across cardiovascular disease, diabetes and chronic kidney disease. The proposed acquisition of ZS Pharma will add a regulatory-stage candidate, ZS-9, to AstraZeneca’s pipeline. The company is focused on the development and commercialization of highly selective, non-systemically absorbed therapeutics to treat renal, cardiovascular, liver and metabolic diseases. Operator of a biopharmaceutical company. Our patient-led strategy is focused on leadership and returning to growth. European Marketing Application Authorisation is also progressing as planned. Christer Gruvris Consensus Forecasts +44 7827 836825 ASTRAZENECA AND ZS PHARMA DISCLAIM ANY INTENT OR For more portfolio, a comorbidity often associated with CKD and CHF patients. US OBLIGATION TO UPDATE ANY FORWARD-LOOKING STATEMENTS AS A RESULT OF DEVELOPMENTS through life changing medicines.
Unfall Sulzdorf Heute, Astrazeneca Pharmaceuticals Lp Phone Number, Starbound Commands Spawnitem, Kreis Bergstraße Zulassungsstelle, Andechser Bio Joghurt Stracciatella, Haus Mieten 57537 Wissen, Mindfactory Grafikkarte Zurückschicken, Liverpool Trikot 19 20, Beamng Drive Systemanforderungen, Marvel Advent Calendar 2020 Characters,